Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies

Audrey Vincent, Aïcha Ouelkdite-Oumouchal, Mouloud Souidi, Julie Leclerc, Bernadette Neve, Isabelle Van Seuningen

World Journal of
Stem Cells

WJSC

World Journal of Stem Cells

Contents

ABOUT COVER

Editorial Board Member of *World Journal of Stem Cells*, Ko-Tung Chang, PhD, Associate Professor, Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan

AIMS AND SCOPE

The primary aim of *World Journal of Stem Cells* (*WJSC*, *World J Stem Cells*) is to provide scholars and readers from various fields of stem cells with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJSC publishes articles reporting research results obtained in the field of stem cell biology and regenerative medicine, related to the wide range of stem cells including embryonic stem cells, germline stem cells, tissue-specific stem cells, adult stem cells, mesenchymal stromal cells, induced pluripotent stem cells, embryoid bodies, embryonal carcinoma stem cells, hemangioblasts, hematopoietic stem cells, lymphoid progenitor cells, myeloid progenitor cells, *etc*.

INDEXING/ABSTRACTING

The *WJSC* is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Biological Abstracts, and BIOSIS Previews. The 2019 Edition of Journal Citation Reports cites the 2018 impact factor for *WJSC* as 3.534 (5-year impact factor: N/A), ranking *WJSC* as 16 among 26 journals in Cell and Tissue Engineering (quartile in category Q3), and 94 among 193 journals in Cell Biology (quartile in category Q2).

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Yan-Xia Xing*

Proofing Production Department Director: *Yun-Xiaojian Wu*

Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies

Audrey Vincent, Aïcha Ouelkdite-Oumouchal, Mouloud Souidi, Julie Leclerc, Bernadette Neve, Isabelle Van Seuningen

ORCID number: Audrey Vincent (0000-0003-0058-2058); Aïcha Ouelkdite-Oumouchal (0000-0002-7048-5555); Mouloud Souidi (0000-0001-6767-8738); Julie Leclerc (0000-0003-1130-7211); Bernadette Neve (0000-0003-1516-1379); Isabelle Van Seuningen (0000-0002-3131-2694).

Audrey Vincent, Aïcha Ouelkdite-Oumouchal, Mouloud Souidi, Julie Leclerc, Bernadette Neve, Isabelle Van Seuningen, Lille University, Institut National de la Santé et de la Recherche Médicale, CHU Lille, UMR-S 1172-Jean-Pierre Aubert Research Center, Lille F-59000, France

Julie Leclerc, Department of Biochemistry and Molecular Biology, Lille University Hospital, Lille F-59000, France

Corresponding author: Isabelle Van Seuningen, PhD, Director, Inserm UMR-S 1172-Jean-Pierre Aubert Research Center, Bâtiment Cancer, 1 Rue Michel Polonovski, Lille F-59045, France. isabelle.vanseuningen@inserm.fr
Telephone: +33-320-298867
Fax: +33-320-538562

Abstract

The recent discovery of cancer cell plasticity, *i.e.* their ability to reprogram into cancer stem cells (CSCs) either naturally or under chemotherapy and/or radiotherapy, has changed, once again, the way we consider cancer treatment. If cancer stemness is a reversible epigenetic state rather than a genetic identity, opportunities will arise for therapeutic strategies that remodel epigenetic landscapes of CSCs. However, the systematic use of DNA methyltransferase and histone deacetylase inhibitors, alone or in combination, in advanced solid tumors including colorectal cancers, regardless of their molecular subtypes, does not seem to be the best strategy. In this review, we first summarize the knowledge researchers have gathered on the epigenetic signatures of CSCs with the difficulty of isolating rare populations of cells. We raise questions about the relevant use of currently available epigenetic inhibitors (epidrugs) while the expression of numerous cancer stem cell markers are often repressed by epigenetic mechanisms. These markers include the three cluster of differentiation CD133, CD44 and CD166 that have been extensively used for the isolation of colon CSCs.and . Finally, we describe current treatment strategies using epidrugs, and we hypothesize that, using correlation tools comparing associations of relevant CSC markers with chromatin modifier expression, we could identify better candidates for epienzyme targeting.

Key words: Cancer stem cells; Colon cancer; Epigenetics; Chromatin modifying enzymes; CD44; CD133; CD166

Core tip: The recent discovery of cancer cell plasticity, *i.e.* their ability to reprogram into cancer stem cells either naturally or under chemotherapy and/or radiotherapy, has changed, once again, the way we consider cancer treatment. In this review, we try to understand why current epigenetic treatments have failed to prove their efficacy in solid tumors including colorectal cancer and we hypothesize that, using correlation tools comparing associations of relevant cancer stem cell markers with chromatin modifier expression, we may identify better candidates for epienzyme targeting.

INTRODUCTION

Hierarchy of the tumor: turning an old concept into a new dogma

Although only recently upgraded as the keystone of the natural history of tumors, the concept of "cancer stem cells (CSCs)" was anticipated several decades ago as researchers soon discovered that cancer cells possessed unequal capacities when it comes to initiating a new tumor or resisting to therapies[1]. Indeed already during the 1960s, ethically disputed experiments of auto-transplantation that were conducted in human patients demonstrated that numerous cancer cells were necessary to establish cancer transplants, giving hints on the rare nature (1/1000000) of tumor-initiating cells[2].

With the arrival of the first commercially available cell sorters, followed by immunocompromised mouse models that allowed selective xenotransplantation of cancer cells, the interest in this cancer cell subpopulation has then been growing exponentially, with the field of hematologic malignancies as pioneers[1-3]. As early stem or progenitor cells were shown to be involved in leukemias and myelo-proliferative disorders, tumor initiating cells have rapidly been renamed "cancer stem cells", hence creating a link with histological observations from the 1850's when pathologists had first hypothesized that tumors could develop from residual embryonic tissues[1-3]. Indeed, CSCs share numerous characteristics with normal embryonic stem cells, such as rareness, cell cycle arrest and quiescence, unlimited self-renewal through asymmetric division, and addiction to stem cell signaling pathways.

In solid tumors, the cancer stem cell (CSC) model (Figure 1B) was initially considered as a concept that could not be applied to all tumor types and was often opposed to the stochastic clonal evolution hypothesis[4,5], where genetic mutations are the major cause of tumor heterogeneity (Figure 1A)[6,7]. Increasing evidence of cancer plasticity, where cells easily exchange their position in the tumor hierarchy, switching from stem to non-stem states[8,9] and also from non-stem to stem states, reconcile these two models (Figure 1C). Indeed, several studies have demonstrated that cancer cells from different types of tumors, including colon cancer, can naturally convert to CSCs in culture, in total absence of therapeutic agents inducing genetic alteration[8]. Additionally, anti-cancer treatments such as chemotherapies[10] or radiotherapy[9] not only participate in the selection of resistant clones in the bulk of a tumor but also induce stemness characteristics in non-stem cancer cells. These findings are transposable to tumors from patients in whom stemness-related aggressiveness (invasion capacities, release of circulating tumor cells) is either innate or acquired after exposure to hypoxia, metabolic stress, and treatments.

More importantly, the extreme cellular plasticity involving rapid phenotype switches between CSCs and their non-stem counterpart is probably mediated by epigenetic mechanisms that are reversible in nature, rather than newly acquired genetic mutations. Indeed, we (unpublished data) and others have shown a systematic equilibrium between CSC marker expressing and non-expressing cells that spontaneously occurs after cell sorting of negative *vs* positive populations[11]. In accordance with epigenetic mechanisms involved in this balance between stem and non-stem cancer cells, CSCs harbor a permissive epigenetic state[12-14], comparable to normal stem cells, while epigenetic profiles of differentiated cells are locked in order

Figure 1 The cancer cell plasticity model reconciles cancer stem cell and stochastic models. A: In the stochastic model, cancer cells are heterogeneous because of accumulation of genetic and epigenetic alterations acquired through excessive proliferation, but most cells are able to proliferate and initiate new tumors; B: In the cancer stem cell model, cancer cells are organized in a hierarchy comparable to normal tissues where CSCs (in purple) are the only cells able to regenerate a tumor with its whole heterogeneity; C: In the cancer plasticity model, cancer cells are able to rapidly switch back and forth between a stem and a non-stem state. CSCs change to non-stem cell most likely occurs through epigenetic programming and silencing of cancer stem cell/pluripotency markers. Reprogramming, leading to induced CSCs (in green) from non-stem cancer cells, can either occur through reversible epigenetic modifications or genetic alterations, hence leading to a new clonal population of cancer cells in the tumor. CSC: Cancer stem cell; iCSC: Induced CSC.

to shape cellular identity and functions. However, numerous genetic alterations may render cancer cell reprogramming more complicated to target. Understanding this flexibility is crucial for the development of new anticancer drugs. Therefore, new therapeutic strategies will have to combine the targeting of the bulk of the tumor and of the CSCs, whether they are pre-existing or induced. Hence, if these different types of CSCs share the same reversible reprogramming mechanisms, epigenetic therapies would represent an interesting strategy (Figure 2).

UNRAVELING THE EPIGENETIC SIGNATURE OF CSCs: A KEY TO UNDERSTANDING CANCER CELL PLASTICITY AND REPROGRAMMING

Current research on induced pluripotent stem cells teaches us that erasing epigenetic marks of the differentiated cell of origin greatly improves reprogramming[15,16].

Figure 2 Epigenetic programming and reprogramming of cancer cells and consequences for therapeutic strategies. New therapeutics will have to combine the targeting of the bulk of the tumor, pre-existing CSCs, and iCSCs through inhibition of cancer cell reprogramming. Epigenetic therapies could inhibit CSCs to sensitize cancer cells to conventional therapies (A, C), inhibit cancer cells reprogramming (B), and inhibit relapse through inhibition of self-renewal (D). CSC: Cancer stem cell; iCSC: Induced CSCs; DNMTi: DNA methyltransferase inhibitor; HDACi: Histone deacetylase inhibitor; TET2i: Ten-eleven-translocation 2 inhibitor; SETD7i: SET domain containing 7 inhibitor; H3K4me3: Trimethylation of lysine 4 on histone 3; H3K9me3: Trimethylation of lysine 9 on Histone 3; H3K27me3: Trimethylation of lysine 27 on histone 3.

Mapping stemness-associated chromatin modifications would surely facilitate the development of therapeutic strategies evoking differentiation of CSCs. Indeed, the "differentiating strategy" has proven its efficiency in certain types of hematologic tumors years ago[17]. On the other hand, these strategies have failed to prove their systematic efficacy in solid tumors, where CSCs may come from multiple origins, including normal differentiated cells[8,18], or stochastic genetic events altering cancer cells along tumor evolution.

Molecular mechanisms involved in the shaping of the cancer epigenetic landscapes, and especially in CSCs, are complex. Genetic alterations leading to loss or gain of epienzyme functions have been described[19], but only rare studies focus exclusively on CSCs. Furthermore, overexpression of epienzymes may not reflect an oncogenic role. The histone methyltransferase enhancer of zeste 2 (EZH2) is the perfect example of this paradox, while its overactivation in certain types of cancers is the sole sign of a compensation mechanisms in cells where histone H3 K27 trimethylation is diluted over excessive proliferation[20-22].

Because of the rareness and diversity of CSCs and the fact that no consensus has been found for markers that would allow their proper isolation, few studies have been able to define clearly the cancer stemness-associated epigenetic profiles. It has been shown, however, that mammary and hepatic CSCs harbor more permissive chromatin profiles, more prone to gene activation, than non-stem cancer cells[12]. They also harbor decreased DNA methylation and trimethylation of lysine 27 on histone H3 at tumor suppressor genes[12]. Similarly, trimethylation of lysine 4 on histone H3 is found preferentially at pluripotency genes such as BMI1, NOTCH1, and WNT1 in CSCs from acute myeloid leukemia patients[13]. CSCs from head and neck carcinomas harbor an epigenetic signature with only 22 differentially methylated genes between cluster of differentiation (CD)-44+ CSCs and CD44 non-stem cancer cell populations[14], pointing out subtle and specific differences between stem and non-stem cancer cells. The same type of signature has been identified in breast tumors[23], but still needs to be defined for CSCs from the different colon cancer molecular subtypes.

The common findings from studies on CSC epigenetic profiles are that CSC markers are either regulated by epigenetic mechanisms in normal and/or cancer cells or harbor different epigenetic profiles between stem and non-stem cancer cells[24]. Alternatively, CSC markers can themselves be directly or indirectly responsible for chromatin modifications through their presence in Polycomb Repressive Complexes (BMI1) or through histone demethylation (JARID1B).

Among CSC markers, CD133 and CD44 have been extensively utilized to isolate

cancer cells with tumorigenic characteristics in numerous types of cancers, including colon cancers in which CD133 predicts low survival. In combination with CD166, these two markers better stratify low, intermediate, and high-risk cases of colorectal cancer[25] (CRC) than the three markers alone. We have shown that combined expression of these three markers is associated with stemness and resistance to 5-fluorouracil (5-FU) in colon cancer cells[26,27]. Interestingly, expression and splicing of these three markers are epigenetically regulated in cancer cells.

Epigenetic regulation of PROM1, encoding the CSC marker CD133

CD133 is a 120 kDa transmembrane glycoprotein that was initially identified in hematopoietic stem cells[28] and is involved in cell-cell interactions and membrane organization, through its binding to phospholipids[29]. CD133 is now used as a stem cell marker in most solid tumors including colorectal cancers[29]. More importantly, CD133 is directly involved in stemness properties as its inhibition alters self-renewal and tumorigenic capacities[30]. CD133 is also associated with metastasis and invasiveness through the decrease of metalloprotease 2 expression. Interestingly, its expression is positively correlated with the expression of ATP-binding cassette (ABC) transporters ABCG1 and ABCG2, hence associating CSC properties to chemo-resistance through the presence of multidrug efflux pumps[28]. CD133 is correlated to poor prognosis in numerous cancers including CRC.

The human PROM1 gene, which encodes CD133 (prominin-1), consists of 28 exons and is localized on chromosome 4p15. The regulation of PROM1 transcription includes five alternative promoters (P1-5) involved in embryonic phase development. PROM1 harbors seven alternative spliced variants, of which the most documented are CD133s1 and CD133s2 (lacking exon 3)[31,32]. Of those only CD133s1 is mainly associated with normal tissue in brain, bone marrow, and blood[31]. CD133s2 expression is widely observed in human fetal tissue and adult tissues and in several cancers, including breast, colon, lung, and pancreatic carcinomas. CD133s2 is also associated with the human stem cell niche[33].

PROM1 expression is inversely correlated with methylation of CpG islands in its promoter in numerous cancer cell lines[34,35]. For example, in glioma tissues, an inverse correlation has been shown between the CpG methylation status of promoter P1 and P2 and expression levels of PROM1 transcripts. Epigenetic regulation of PROM1 also includes histone modifications, since synergistic effects are observed when using histone deacetylase (HDAC) inhibitors in combination with DNA methyltransferase (DNMT) inhibitors to re-express the cell surface marker CD133 in ovarian cancer cells[24].

Epigenetic regulation of CD44

CD44 is a transmembrane glycoprotein interacting with components of the extracellular matrix including hyaluronic acid, collagens, fibronectins, integrins, and laminin[36]. These interactions induce cytoskeleton modifications and activation of signaling pathways involved in cell adhesion and migration. CD44 expression has been associated with tumor progression, epithelial-to-mesenchymal transition[37], and poor survival in colon cancers[38]. Mutations have been described in solid tumors, suggesting its implication in carcinogenesis[37]. Most importantly, CD44-variant-6 (v6) is a well-recognized marker of colon and gastric CSCs[39,40].

The human CD44 gene consists of 20 exons and is located on chromosome 11p13. Exons 1-5 and 15-19 encode homologous N-ter (extracellular) and C-ter (extracellular, transmembrane and intracellular) domains respectively forming the standard isoform CD44s. Alternative splicing of exons 5a-14 result in different variants/isoforms of CD44 (CD44v). CD44 variants are overexpressed in numerous types of solid tumors including pancreatic (CD44v2-6), breast (CD44v6/v8-10), prostate (CD44v2/v6), head and neck (CD44v3), and colon (CD44v6/v10) cancers[37]. In contrast with CD44s variant that is absent from mouse normal intestinal stem cells[37], CD44 variants (CD44v4-10) have been associated with normal and cancer stemness. For instance, CD44v6 and CD44v4 are largely overexpressed in stem cells compared to their progeny (transit-amplifying cells). CD44 variants, and not CD44s, are involved in adenoma formation in mouse models of familial polycystic adenomas[41]. Similarly, expression of CD44v6 is restricted to colon CSCs and is associated with worse survival in patients with CRC[39]. In most studies, CD44v4-10 variants are associated with aggressiveness, resistance, metastasis, and poor prognosis in solid tumors including colon cancers.

Epigenetic regulation of the CD44 gene has recently been described. DNA methylation at CpG islands located in the promoter and histone H3 acetylation regulate its silencing or expression[37], respectively. DNMT inhibition induced DNA methylation and histone modification changes at the CD44 gene promoter, increasing CD44 mRNA levels in cancer cell lines[37,42]. More importantly, alternative splicing of

CD44 and, hence, the expression of CSC specific variants is epigenetically regulated. Indeed, accumulation of histone H3 lysine 9 trimethylation and HP1 stabilizes pre-mRNA binding to the chromatin and therefore facilitates exon inclusion[43].

Epigenetic regulation of ALCAM encoding the CSC marker CD166

CD166 is a member of the immunoglobulin superfamily and is engaged in homophilic or heterophilic interactions with the cell surface receptor CD6. CD166, which is expressed on antigen-presenting cells, is involved in maturation of CD6-expressing resting T-cells and is also expressed in mesenchymal stem cells, neural cells, osteoblasts, and stromal cells of the bone marrow. It is involved in hematopoiesis, development of central and peripheral nervous system, sense organs, and differentiation of endothelial as well as epithelial lineages[44]. CD166 has proven its relevance as a CSC marker alone or in combination with CD44 in several studies including studies on colon cancer cell lines[45,46].

The human gene ALCAM, encoding CD166, is located on chromosome 3q.13 and consists of 16 exons. A soluble isoform, produced through alternative splicing, has been described, but its role remains unknown[47].

The ALCAM promoter harbors several CpG islands regulated by DNA methylation. It has been shown that the DNMT inhibitor 5-Aza-2'-deoxycytidine increased its expression in breast cancer cells[48], hence raising questions about the use of these inhibitors in breast cancer patients.

Interestingly, the three discussed CSC and survival markers (CD44, CD166, and CD133, Figure 3) are not only epigenetically regulated in cancer cells, but our transcriptomic analyses of public CRC data also revealed that the combined expression of these markers in colon cancer is correlated with a specific panel of epienzyme expression (both positive and negative correlations are listed in Tables 1-6).

EPIENZYME CORRELATION WITH COLON CSC MARKERS: A HINT FOR SUCCESS IN EPIGENETIC THERAPEUTIC STRATEGIES?

Current epigenetic strategies

Most solid tumors, including CRC, acquire chemoresistance over time. In addition to expected chemo-induced genetic alterations, the molecular mechanisms involved include transcriptional plasticity that is regulated epigenetically, for example by multiple DNA methylation changes at CpG islands[49]. Contrary to genetic alterations, epigenetic modifications are potentially reversible, paving the way for novel cancer therapies.

This past decade has seen the emergence of many epigenetic therapies, especially DNA hypomethylating drugs (DNA methyltransferase inhibitors) and HDAC inhibitors (HDACi), as well as lysine-specific histone demethylase-1, EZH2 inhibitors, and many others[50].

Epigenetic drugs have shown beneficial effects for the treatment of hematological malignancies and led to the approval of epidrugs like 5-azacitidine, decitabine, vorinostat, romidepsin, belinostat, and panobinostat for patient treatment[50]. In contrast, clinical trials assessing the efficacy of these epigenetic drugs in monotherapies for CRC and other solid tumors failed to improve clinical outcomes with, in some cases, no response at all[51], never passing the phase III trial necessary for approval (clinical trials for CRC listed in Tables 1-6).

Several hypotheses could be raised regarding this apparent lack of efficacy of epidrugs for solid tumors. First, compared to hematologic malignancies, solid tumors harbor a weaker penetrance of mutations in genes encoding chromatin modifying enzymes[19]. Second, the pleiotropic effect of current epidrugs leads to the combined inhibition of many members of a given family of epienzymes that have a broad spectrum of action and opposing roles in cancer cells. Third, and most importantly, cancer cell plasticity, and the switch between stem and non-stem state, is orchestrated by complex mechanisms, including epigenetic silencing of CSC markers and pluripotency genes. Despite genetic heterogeneity among cancer cells[52] (due to stochastic or chemo-/radio-induced mutations along tumor evolution/treatment), DNA methylation and histone deacetylation seem to represent typical mechanisms involved in repressing stemness markers in non-stem cancer cells, as previously demonstrated for CD44, CD133, and CD166. Therefore, inhibiting DNMT and HDAC may result in increased expression of CSC markers[37,42,48] along with an increased stemness potential. Last, patients included in these clinical trials often present metastatic or advanced disease and are recruited regardless of the molecular subtype

Table 1 Negative correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic writers

Family/gene symbol	Epidrug/chemical probe	Clinical trials for CRC	Results/status	Z-score	P value
DNA methyltransferases	5-azacytidine (Vidaza)[1]	Early Phase I to phase II[63,64]	No OR[63,65]		
	5-aza-2'-désoxycytidine (Decitabine)[1]	Phase I to phase II[66-68]	No OR[66]; beneficial with Panitumumab[68]		
	EGCG (Green tea extract)	Preclinical spheroid-derived cancer stem cell xenograft models[69]	Sensitization to chemotherapy		
	Zebularine	Preclinical xenografts[70]	Anticancer activity		
	RG108, Procainamide[2]				
DNMT3A, DNMT3B, DNMT3L				-2.788/-4.848/-4.321	< 0.005
Activating Lysine methyltransferases					
SETD6	vp22-RelA302-316[3][71]			-4.641	3.47E-06
SETD1A				-4.375	1.212E-05
Repressive Lysine methyltransferases					
SMYD5	-			-4.514	6.371E-06
EHMT2	UNC0224[3], UNC0642[3], BIX-01294[3]			-4.322	1.545E-05
SETDB2	-			-3.6	0.0003176
PRDM13	-			-3.442	< 0.005
SUV39H1, SUV39H2	Chaetocin[3]			-3.422/-2.934	0.0006216
PRDM12	-			-3.089	0.00201
EZH1	UNC1999[3]			-2.787	0.005314
EZH2	CPI-1205[2,4], EPZ-6438 (Tazemetostat)[2], DZNep[2], UNC1999[3]			-2.495	0.01259
Arginine methyltransferases					
CARM1	MS049[3], SGC2085[3], TP-064[3][72]			-3.812	0.0001381
PRMT1	MS023[3][72]			-3.659	0.0002534
PRMT6	MS023[3], MS049[c], EPZ020411[3][72], 6'-methyleneamine sinefungin[3][73]			-3.521	0.0004301
Histone acetylation					
KAT2A	CPTH2[3][74], γ-butyrolactone[3] (MB-3)[75]			-4.683	2.823E-06
NAA10, NAA16, NAA20, NAA38, NAA40	-			-4.335/-3.255/-3.786/-3.801/-2.665	< 0.01
NAT8, NAT9	-			-2.573/-3.995	< 0.01
NCOA5, NCOA6	-			-3.238/-3.112	< 0.002
Histone phosphorylation					
BAZ1B	-			-2.374	0.01758
Histone glycosylation					
OGT	-			-3.172	0.001512

[1]Approved for the treatment of other diseases;
[2]Used in clinical trials for other diseases;
[3]Not yet used in clinical trials;
[4]Activator. CRC: Colorectal cancer; OR: Objective response.

of cancer. As aberrant DNA methylation is an early step of carcinogenesis, advanced disease may not be the relevant stage for treatments with DNMTi and HDACi.

To refine these treatment strategies, tumor grade, heterogeneity, and subtypes of cancers will have to be considered. Indeed, determining which tumors will benefit from epigenetic differentiation strategies[53] and which tumors would acquire stemness capacities after epigenetic resetting is mandatory. Hence, modulating epigenetic alterations to sensitize cancer cells to other conventional therapies[54] or to lower their aggressiveness seems to be a reasonable goal when it comes to epigenetic strategies for advanced disease, as shown by numerous studies on cancer cell lines[53]. HDAC and DNMT inhibitors, used alone or in combination, are able to sensitize resistant cancer cells and their use after conventional or targeted therapies have

Figure 3 Survival analysis for CD133/CD44/CD166 expression profiles in colorectal cancer. The association of CD133/CD44/CD166 transcript expression with cancer survival in the COADREAD Cancer Genome Atlas dataset was analyzed using the SurvExpress portal[62]. Kaplan-Meier plot and Cox survival statistics were established with maximized risk group assessment (466 patients with 255 in low *vs* 211 in high risk profile). The log rank for equal curves indicated a significant difference (*P* value = 0.0007) with a hazard ratio of 2.12 (95%CI: 1.35-3.31, *P* value = 0.0009).

proven their efficacy in clinical trials[55]. For instance, treatment with 5-azacitidine or 5-Aza-2′-deoxycitidine increases sensitivity of colon cancer cells to irinotecan and 5-FU[56]. Irinotecan sensitivity with DNMTi was confirmed in *in vivo* CRC models showing tumor regression and increased survival in contrast with monotherapies. The same results were observed with the combination of 5-azacitidine and a BRAF inhibitor in CRC xenograft models[57]. Synergetic therapies were also observed with HDACi in combination with 5-FU. Indeed, trichostatine A in combination with 5-FU suppresses colon cancer cell viability[58]. However, initiating re-differentiation in CSCs remains a challenge dependent on the characteristics of each tumor type and with their specific genetic alterations.

Molecular subtypes of CRC or chemoresistance also predict how and whether or not patients will benefit from existing epidrug treatments. For instance, it has been shown that treatment with 5-azacitidine can restore chemosensitivity to irinotecan in microsatellite stable CRC cell lines but not in microsatellite instable CRC cell lines[56]. Moreover, microsatellite instability CRC status is associated with the hypermethylation of glutathione peroxidase 3, a gene encoding an antioxidant selenoprotein involved in drug metabolism. In this case, treatment with 5-azacitidine induced an increase of glutathione peroxidase 3 expression and a decrease of chemosensitivity to oxaliplatin in microsatellite instability CRC cell lines[59]. These findings emphasize the need for personalized therapies that consider CRC interindividual heterogeneity and classification.

Exploring new avenues for colon cancer treatment

In order to better anticipate how colon CSCs will respond to the different existing therapies, we analyzed TCGA_COADREAD data of 379 colon cancer patients using LinkedOmics[60]. With this meta-analysis we assessed the correlation Z-score estimate (Stouffer method-based) and a *P* value between the combined expression of the three colon CSC markers CD133, CD44, and CD166 and an exhaustive list of known chromatin modifying enzymes (epigenetic writers and erasers) and chromatin binding proteins (epigenetic readers). The observed negative and positive correlation of expression between the three CSC markers and a significant number of epienzymes are highlighted in Tables 1 to 6.

Strikingly, DNMT3A, DNMT3B, and DNMT3L, the DNA methyltransferases that are responsible for *de novo* DNA methylation, showed a negative correlation score with the combined expression of the three CSC markers studied (Table 1), while the expression of DNMT1, responsible for DNA methylation maintenance, was not significantly correlated with the combination of these markers (-2 < score < 2). Similarly, three class I and II HDAC as well as two sirtuins were found negatively correlated to the combination of markers (Table 2). None of the known HDAC were found positively correlated with the expression of the three CSC markers. This strongly suggests that inhibiting DNMT or HDAC activity would have no effect in

colon cancers overexpressing CSC markers (and potentially harbor high stemness properties) but may have adverse effect in low-expressing and maybe less aggressive colon cancers. These data are in accordance with disappointing clinical trials that have been conducted so far with these inhibitors in colon cancer patients. Interestingly, our analyses suggest that another strategy to regulate DNA methylation in colon CSCs may be the inhibition of the methylcytosine dioxygenase TET2, known to trigger DNA demethylation and found correlated to CSC marker expression in our analyses (Table 3).

The correlation scores we obtained for other chromatin writers, readers, and erasers seem more specific to the enzyme itself than to their role in the shaping of epigenetic landscapes (Tables 1-6).

We found a negative correlation between the expression of the three markers and several histone lysine methyltransferases associated with the establishment of constitutive or facultative heterochromatin, including EZH2 that has recently emerged as one of the new favorite targets for epigenetic therapies[20] (Table 1). These estimated scores in colon cancer expressing CD133, CD44, and CD166 suggest that an activator of EZH2, such as CPI-1205, may have better efficacy than known inhibitors in clinical trials to influence cancer stemness and are in accordance with a protective role of EZH2 in cell differentiation. Similarly, expression of EHMT2 (also known as G9A and KMT1C), encoding another lysine methyltransferase that also recently raised interests in the epidrug field, was inversely correlated with the three CSC markers expression (Table 1).

Only few lysine methyltransferases associated with gene activation were found correlated or inversely correlated with the combined expression of the three markers. Among them, SETD7 (Table 4), but not SETD6 (Table 1), may be a good candidate to inhibit stemness in colon cancer cells.

Recently, small molecules that can target specific bromodomains have been extensively developed[61]. Bromodomains are part of a family of epigenetic readers that play pivotal roles in transcriptional regulation through the binding of acetylated histones and the recruitment of other epienzymes in epigenetic complexes at specific sites. We found only a few bromodomain-containing proteins whose expression was positively (BPTF, BAZ2B, Table 5) or negatively (BRD7, Table 6) correlated to the combined expression of the three CSC markers.

Among epigenetic readers, methylated DNA binding proteins have probably been overlooked as epidrug targets since expression of both MBD1 and MBD2 is positively correlated with CSC markers (Table 5).

Targeting members of the lysine-specific histone demethylase family of histone demethylases using inhibitors such as GSK-J1 may also be a good option since only a few of them are inversely correlated with the three CSC markers while KDM3B, KDM4B/C, KDM5B, KDM6A (UTX), and KDM6B (JMJD3) are positively correlated to their expression (Table 3).

Finally, JAK1/2 kinases, which possess a histone phosphorylation activity and are the targets of numerous inhibitors already tested in the clinic, mainly for other diseases, should probably be reconsidered for colon cancer patients with high expression of CD133, CD44, and CD166 or after conventional therapies. Indeed, our meta-analyses suggest that their expression is positively correlated to the expression of the three CSC markers (Table 4).

As mentioned above, CD44, CD133, and CD166 are potent markers of CSCs from multiple tissues including digestive (gastric, pancreatic) and non-digestive cancers in which they are epigenetically regulated. Therefore, these considerations could be largely applicable to other types of cancers, in which correlation studies between epienzymes and CSC markers may be of great interest.

PERSPECTIVES

Although epigenetic therapies are conceptually very promising, several pitfalls will have to be overcome in order to take a step forward in clinical trials for solid tumors. First, while intra-tumor and inter-individual heterogeneity of CRC is now evident, epigenetic landscapes and epienzyme activity will have to be studied in all types of tumor cells. Single cell approaches will be very useful to circumvent the difficulty of exploring rare CSCs from different CRC consensus molecular subtypes. Second, studies to prove causal correlations between epienzyme expression and the control of stemness will be mandatory in order to clear up confusion relative to the oncogenic or tumor suppressive roles of chromatin modifiers. Finally, the major difficulty for the design of new epidrugs is to target efficiently a single member of entire families of epienzymes that have homologous domains but different roles in stemness. To

Table 2 Negative correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic erasers

Family/gene symbol	Epidrug/chemical probe	Clinical trials for CRC	Results	Z-score	P value
Histone deacetylation (Zinc-dependent)					
	Acide valproïque[1]	I to II	In combination: OR in 64% patients or SD[76,77]		
	Belinostat[2], Apicidin[3]				
	Entinostat	I to I/II	No OR[78] or SD[79]		
	Panobinostat	I	PR and SD in combination with Bevacizumab[80]		
	Vorinostat (SAHA)	I to II	No OR[81,82]; SD and PR with Bortezomib or 5FU and leucovorin or Doxorubicin[83-85]		
	Trichostatine A[2]				
	Mocetinostat[2]				
	Sodium phenylbutyrate[2]	I	In combination with 5-FU: SD[86]		
Class I	Romidepsin (Istodax)[1]	II	Ineffective[86]		
	CI-994	I	PR in combination with carboplatin and placlitaxel[87]		
HDAC8	TM-2-51[4], CUDC-101[2], Pracinostat[2], Ricolinostat[2], Citarinostat[2], Abexinostat[2], Quisinostat[3], PCI-34051[3]			-2.527	0.0115
Class IIa (1 catalytic site, mainly cytoplasmic)					
HDAC5	CUDC-101[2], Pracinostat[2], Domatinostat[2], Quisinostat[3], LMK-235[3], TMP195[3], TMP269[3]			-4.133	3.581E-05
Class IIb (2 catalytic sites, mainly cytoplasmic)					
HDAC10	CUDC-101[2], CUDC-907[2], Pracinostat[2], Domatinostat[2], Abexinostat[2], Tucidinostat[2], Quisinostat[3]			-3.17	0.001525
Histone deacetylation NAD+ dependent (Class III)					
	Resveratrol[4]	I	Reduced cell proliferation[88]		
	Salermide[3][89]				
SIRT6	OSS_128167[3]			-3.467	0.0005257
SIRT7				-2.582	0.009835
Histone demethylation					
LSD family of demethylases					
	ORY-1001[3], (±)-tranylcypromine[3]				
KDM2B	-			-3.54	0.0004003
KDM4D	-			-2.704	0.006848
JmjC containing lysine demethylases					
	JIB-04[3]				
JMJD6	IOX1[3]			-2.59	0.00961
JMJD5	IOX1[3]			-2.588	0.009654

[1]Approved for the treatment of other diseases;
[2]Used in clinical trials for other diseases;
[3]Not yet used in clinical trials;
[4]Activator. CRC: Colorectal cancer; OR: Objective response; SD: Stable disease; PR: Partial response.

Table 3 Positive correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic erasers

Family/gene symbol	Putative epidrug/chemical probe	Z-score	P value
DNA demethylation			
TET2	-	5.968	2.40E-09
Histone demethylation			
LSD family of demethylases			
	ORY-1001[3], (±)-tranylcypromine[3]		
KDM3B		5.636	1.74E-08
KDM4B	CP2[3][90]	5.212	1.87E-07
KDM4C	CP2[3][90]	3.895	9.81E-05
KDM5B	CPI-455[3], AS-8351[3], 59[3] (KDOAMA-25[3])[90]	9.092	9.72E-20
KDM6A	GSK-J1[3]	2.84	0.00451
KDM6B	GSK-J1[3]	4.014	5.98E-05

[1]Approved for the treatment of other diseases; [2]Used in clinical trials for other diseases; [3]Not yet used in clinical trials.

circumvent this difficulty, increasing specificity by targeting epigenetic complexes and therefore epienzyme-epienzyme interactions may be a better option for new designs. Based on these considerations, epigenetic personalized medicine will be truly envisioned.

Table 4 Positive correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic writers

Family/gene symbol	Epidrug/chemical probe	Clinical trials for CRC	Results/status	Z-score	P value
Histone acetyltransferases					
EP300	Curcumin[1]	Early phase I to III	Low bioavailability[91]	2.513	0.01198
	Garcinol[3], C646[3]				
NCOA1	Bufalin[2][92]			5.45	5.04E-08
NCOA4	-			4.183	2.88E-05
NCOA7	-			5.788	7.14E-09
KAT2B	Ischemin[3][93]			6.514	7.31E-11
Activating Lysine methyltransferases					
ASH1L	-			2.591	0.009565
SMYD1	-			2.739	0.00616
SETD7	PFI-2[3]			5.11	3.23E-07
Repressing Lysine methyltransferases					
PRDM8	-			3.411	0.0006465
Putative Lysine methyltransferase					
PRDM10	-			2.448	0.01438
Arginine methyltransferases					
PRDM1	-			2.874	0.004056
PRMT2	-			2.901	0.003726
Histone ubiquitination					
UBE2B	-			2.748	0.005991
UBE2H	-			5.809	6.30E-09
Histone phosphorylation					
JAK1	Ruxolitinib	Phase I and II	No benefit over Regorafenib alone[94]	7.739	1.01E-14
	Baricitinib[2], Momelotinib[2], Filgotinib[2], Decernotinib[2], Cerdulatinib[2], Solcitinib[2], Oclacitinib maleate[2]				
JAK2	Ruxolitinib	Phase I and II	No benefit over Regorafenib alone[94]	6.7	2.09E-11
	Gandotinib[2], AZD1480[2], BMS-911543[2], AT9283[2], XL019[2], Baricitinib[2], Momelotinib[2], Filgotinib[2], Decernotinib[2], Cerdulatinib[2], JAK2/HDAC Dual Inhibitors[3][95]				
Histone biotinylation					
BTD	Biotinyl-methyl 4-(amidomethyl)benzoate[3][96]			4.379	1.19E-05

[1]Approved for the treatment of other diseases;
[2]Used in clinical trials for other diseases;
[3]Not yet used in clinical trials. CRC: Colorectal cancer.

Table 5 Positive correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic readers

Family/gene symbol	Epidrug/chemical probe	Z-score	P value
Methylated DNA binding			
MBD1	-	2.593	0.009517
MBD2	-	3.477	0.0005076
ZBTB4	-	5.496	3.89E-08
Methylated histone binders			
Zinc finger, PHD-type			
DPF3		3.503	0.0004602
Bromodomain	Apabetalone[2], Bromosporine[3]		

Family/gene symbol	Putative epidrug/chemical probe	Z-score	P value
BPTF		2.621	0.008773
BAZ2B	GSK2801[3]	4.791	1.66E-06
Tudor domain			
TDRD1	-	2.459	0.01394
TP53BP1	-	2.965	0.003029
Other cofactors of epigenetic complexes			
RBBP5	-	2.966	0.003014
TADA2B	-	3.382	0.0007189
ELP2	PLX-4720[3]	3.277	0.00105
ELP3	-	2.622	0.00875
TAB2	-	2.551	0.01074
NCOR1	-	3.62	0.0002949
Chromodomain (Chromatin Organization Modifier Domain)			
CHD1, CHD3, CHD9	-	3.007/4.099/4.367	< 0.003

[1]Approved for the treatment of other diseases;
[2]Used in clinical trials for other diseases;
[3]Not yet used in clinical trials.

Table 6 Negative correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic readers

Family/gene symbol	Putative epidrug/chemical probe	Z-score	P value
Methylated DNA binding			
MBD3	-	-3.601	0.0003174
ZBTB38 (Kaiso family)	-	-2.557	0.01055
Histone binders			
Bromodomains			
BRD7	BI7273[3], BI-9564[3], TP-472[3][97]	-4.906	9.301E-07
Zinc finger, Plant Homeodomain (PHD)-type			
ING1, ING5	-	-2.544/-4.255	< 0.05
PHF20	-	-3.094	0.001973
PHF14	-	-2.934	0.003344
PHF5A	-	-2.521	0.01171
DPF1	-	-2.78	0.00543
Tudor domain			
TDRKH	-	-2.755	0.005875
WD40 motif			
EED	A-395[3][98]	-4.307	1.652E-05
Other cofactors of epigenetic complexes			
DPY30	-	-3.549	0.0003863
WDR5	OICR-9429[3]	-3.31	0.0009321
TADA2A		-2.473	0.01341

[1]Approved for the treatment of other diseases; [2]Used in clinical trials for other diseases;
[3]Not yet used in clinical trials.

ACKNOWLEDGEMENTS

REFERENCES

1   **D'Andrea V**, Guarino S, Di Matteo FM, Maugeri Saccà M, De Maria R. Cancer stem cells in surgery. *G Chir* 2014; **35**: 257-259 [PMID: 25644725]

2   **Southam CM**, Brunschwig A. Quantitative studies of autotransplantation of human cancer. *Cancer* 1961;
     14: 971-978 [DOI: 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O]
3   **Huntly BJ**, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. *Nat Rev
     Cancer* 2005; **5**: 311-321 [PMID: 15803157 DOI: 10.1038/nrc1592]
4   **Reya T**, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and CSCs. *Nature* 2001; **414**: 105-111
     [DOI: 10.1038/35102167]
5   **Shackleton M**, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus
     clonal evolution. *Cell* 2009; **138**: 822-829 [PMID: 19737509 DOI: 10.1016/j.cell.2009.08.017]
6   **Basicević V**, Kleut-Jelić R, Orovcanec M, Vuković D. [Frequency and significance of lambliasis in the
     clinical material]. *Med Pregl* 1972; **25**: 323-325 [PMID: 4636056 DOI: 10.1126/scitranslmed.aaa1408]
7   **Turajlic S**, McGranahan N, Swanton C. Inferring mutational timing and reconstructing tumour
     evolutionary histories. *Biochim Biophys Acta* 2015; **1855**: 264-275 [PMID: 25827356 DOI:
     10.1016/j.bbcan.2015.03.005]
8   **Frohman LA**, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of
     growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product
     cleaved at the NH2 terminus. *J Clin Invest* 1986; **78**: 906-913 [PMID: 3093533 DOI:
     10.1073/pnas.1102454108]
9   **Bardají JL**, Villarroel MT, Vázquez de Prada JA, Ruano J, Olalla JJ, Martín Durán R, Martín Lorente JL,
     López Morante A. [Acute pericarditis and cardiac tamponade as the initial manifestation of ulcerative
     colitis]. *Rev Esp Cardiol* 1988; **41**: 257-260 [PMID: 3413333 DOI: 10.1002/stem.1058]
10   **Freitas DP**, Teixeira CA, Santos-Silva F, Vasconcelos MH, Almeida GM. Therapy-induced enrichment of
     putative lung cancer stem-like cells. *Int J Cancer* 2014; **134**: 1270-1278 [PMID: 24105655 DOI:
     10.1002/ijc.28478]
11   **Sugiura T**, Iwasaka T, Takayama Y, Takahashi N, Matsutani M, Inada M. The factors associated with
     fascicular block in acute anteroseptal infarction. *Arch Intern Med* 1988; **148**: 529-533 [PMID: 3341854
     DOI: 10.1038/bjc.2012.126]
12   **Yasuda H**, Soejima K, Watanabe H, Kawada I, Nakachi I, Yoda S, Nakayama S, Satomi R, Ikemura S,
     Terai H, Sato T, Suzuki S, Matsuzaki Y, Naoki K, Ishizaka A. Distinct epigenetic regulation of tumor
     suppressor genes in putative cancer stem cells of solid tumors. *Int J Oncol* 2010; **37**: 1537-1546 [PMID:
     21042723 DOI: 10.3892/ijo_00000807]
13   **Yamazaki J**, Estecio MR, Jelinek J, Graber D, Lu Y, Ramagli L, Liang S, Kornblau SM, Issa JP.
     Genome-wide epigenetic analysis of CSCs in acute myeloid leukemia. ASH Annual Meeting; 2010.
     American Society of Hematology. 2010
14   **Furusawa J**, Zhang H, Vural E, Stone A, Fukuda S, Oridate N, Fang H, Ye Y, Suen JY, Fan CY. Distinct
     epigenetic profiling in head and neck squamous cell carcinoma stem cells. *Otolaryngol Head Neck Surg*
     2011; **144**: 900-909 [PMID: 21493336 DOI: 10.1177/0194599811398786]
15   **Bar-Nur O**, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific
     differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. *Cell Stem
     Cell* 2011; **9**: 17-23 [PMID: 21726830 DOI: 10.1016/j.stem.2011.06.007]
16   **el-Fiky SM**, Kolkaila AM, Dawd DS, Wahab RM. Histochemical aspects of hydatidiform mole and
     choriocarcinoma. *Acta Histochem* 1973; **47**: 115-123 [PMID: 4134946 DOI: 10.1016/j.jacc.2014.04.056]
17   **Cimino G**, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F,
     Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C.
     Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-
     risk acute myeloid leukemia. *Cancer Res* 2006; **66**: 8903-8911 [PMID: 16951208 DOI:
     10.1158/0008-5472.CAN-05-2726]
18   **Vincent A**, Van Seuningen I. On the epigenetic origin of cancer stem cells. *Biochim Biophys Acta* 2012;
     1826: 83-88 [PMID: 22495062 DOI: 10.1016/j.bbcan.2012.03.009]
19   **Timp W**, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the
     expense of the host. *Nat Rev Cancer* 2013; **13**: 497-510 [PMID: 23760024 DOI: 10.1038/nrc3486]
20   **Kim KH**, Roberts CW. Targeting ezh2 in cancer. *Nat Med* 2016; **22**: 128-134 [DOI: 10.1038/nm.4036]
21   **van Vlerken LE**, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt
     EM. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a
     functional cancer stem cell reporter. *Stem Cells Transl Med* 2013; **2**: 43-52 [PMID: 23283488 DOI:
     10.5966/sctm.2012-0036]
22   **Tan J**, Yang X, Jiang X, Zhou J, Li Z, Lee PL, Li B, Robson P, Yu Q. Integrative epigenome analysis
     identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically
     inactivated in colorectal cancer. *Cell Death Dis* 2014; **5**: e1324 [PMID: 25032847 DOI:
     10.1038/cddis.2014.283]
23   **Sun JG**, Liao RX, Qiu J, Jin JY, Wang XX, Duan YZ, Chen FL, Hao P, Xie QC, Wang ZX, Li DZ, Chen
     ZT, Zhang SX. Microarray-based analysis of microRNA expression in breast cancer stem cells. *J Exp Clin
     Cancer Res* 2010; **29**: 174 [PMID: 21192833 DOI: 10.1186/1756-9966-29-174]
24   **Baba T**, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S,
     Fujii S, Marks JR, Berchuck A, Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of
     CD133+ ovarian cancer cells. *Oncogene* 2009; **28**: 209-218 [PMID: 18836486 DOI:
     10.1038/onc.2008.374]
25   **Horst D**, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers
     CD133, CD44, and CD166 in colorectal cancer. *Cancer Invest* 2009; **27**: 844-850 [PMID: 19626493 DOI:
     10.1080/07357900902744502]
26   **Corvaisier M**, Bauzone M, Corfiotti F, Renaud F, El Amrani M, Monté D, Truant S, Leteurtre E,
     Formstecher P, Van Seuningen I, Gespach C, Huet G. Regulation of cellular quiescence by YAP/TAZ and
     Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse. *Oncotarget* 2016; **7**:
     56699-56712 [PMID: 27527859 DOI: 10.18632/oncotarget.11057]
27   **Touil Y**, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois
     C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM,
     Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G. Colon cancer cells escape 5FU
     chemotherapy-induced cell death by entering stemness and quiescence associated with c-Yes/YAP
     axis. *Clin Cancer Res* 2014; **20**: 837-846 [PMID: 24323901 DOI: 10.1158/1078-0432.CCR-13-1854]
28   **Jang JW**, Song Y, Kim SH, Kim J, Seo HR. Potential mechanisms of CD133 in cancer stem cells. *Life Sci*
     2017; **184**: 25-29 [PMID: 28697984 DOI: 10.1016/j.lfs.2017.07.008]
29   **Ren F**, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. *World J*

Gastroenterol 2013; **19**: 2603-2611 [PMID: 23674867 DOI: 10.3748/wjg.v19.i17.2603]

30   **Li Z**. CD133: a stem cell biomarker and beyond. *Exp Hematol Oncol* 2013; **2**: 17 [PMID: 23815814 DOI: 10.1186/2162-3619-2-17]

31   **Tabu K**, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, Tanino M, Nishihara H, Tanaka S. Promoter hypomethylation regulates CD133 expression in human gliomas. *Cell Res* 2008; **18**: 1037-1046 [PMID: 18679414 DOI: 10.1038/cr.2008.270]

32   **Fargeas CA**, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants - an update. *Tissue Antigens* 2007; **69**: 602-606 [PMID: 17498271 DOI: 10.1111/j.1399-0039.2007.00825.x]

33   **Yu Y**, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. *J Biol Chem* 2002; **277**: 20711-20716 [PMID: 12042327 DOI: 10.1074/jbc.M202349200]

34   **Irollo E**, Pirozzi G. CD133: to be or not to be, is this the real question? *Am J Transl Res* 2013; **5**: 563-581 [PMID: 24093054]

35   **Friel AM**, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. *Reprod Biol Endocrinol* 2010; **8**: 147 [PMID: 21122138 DOI: 10.1186/1477-7827-8-147]

36   **Yan Y**, Zuo X, Wei D. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. *Stem Cells Transl Med* 2015; **4**: 1033-1043 [PMID: 26136504 DOI: 10.5966/sctm.2015-0048]

37   **Chen C**, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. *J Hematol Oncol* 2018; **11**: 64 [PMID: 29747682 DOI: 10.1186/s13045-018-0605-5]

38   **Xia P**, Xu XY. Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses. *Oncotarget* 2016; **7**: 45538-45546 [PMID: 27323782 DOI: 10.18632/oncotarget.9998]

39   **Todaro M**, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. *Cell Stem Cell* 2014; **14**: 342-356 [PMID: 24607406 DOI: 10.1016/j.stem.2014.01.009]

40   **Eom DW**, Hong SM, Kim G, Bae YK, Jang KT, Yu E. Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. *Appl Immunohistochem Mol Morphol* 2015; **23**: 682-688 [PMID: 25710579 DOI: 10.1097/PAI.0000000000000140]

41   **Zeilstra J**, Joosten SP, van Andel H, Tolg C, Berns A, Snoek M, van de Wetering M, Spaargaren M, Clevers H, Pals ST. Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. *Oncogene* 2014; **33**: 665-670 [PMID: 23318432 DOI: 10.1038/onc.2012.611]

42   **Müller I**, Wischnewski F, Pantel K, Schwarzenbach H. Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications. *BMC Cancer* 2010; **10**: 297 [PMID: 20565761 DOI: 10.1186/1471-2407-10-297]

43   **Saint-André V**, Batsché E, Rachez C, Muchardt C. Histone H3 lysine 9 trimethylation and HP1γ favor inclusion of alternative exons. *Nat Struct Mol Biol* 2011; **18**: 337-344 [PMID: 21358630 DOI: 10.1038/nsmb.1995]

44   **Weidle UH**, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. *Cancer Genomics Proteomics* 2010; **7**: 231-243 [PMID: 20952758]

45   **Dalerba P**, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci USA* 2007; **104**: 10158-10163 [PMID: 17548814 DOI: 10.1073/pnas.0703478104]

46   **Kemper K**, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. *Oncotarget* 2010; **1**: 387-395 [PMID: 21311095 DOI: 10.18632/oncotarget.101003]

47   **Ikeda K**, Quertermous T. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. *J Biol Chem* 2004; **279**: 55315-55323 [PMID: 15496415 DOI: 10.1074/jbc.M407776200]

48   **King JA**, Tan F, Mbeunkui F, Chambers Z, Cantrell S, Chen H, Alvarez D, Shevde LA, Ofori-Acquah SF. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. *Mol Cancer* 2010; **9**: 266 [PMID: 20929568 DOI: 10.1186/1476-4598-9-266]

49   **Wei SH**, Brown R, Huang TH. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? *Ann N Y Acad Sci* 2003; **983**: 243-250 [PMID: 12724229 DOI: 10.1111/j.1749-6632.2003.tb05979.x]

50   **Baretti M**, Azad NS. The role of epigenetic therapies in colorectal cancer. *Curr Probl Cancer* 2018; **42**: 530-547 [PMID: 29625794 DOI: 10.1016/j.currproblcancer.2018.03.001]

51   **Azad N**, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. *Nat Rev Clin Oncol* 2013; **10**: 256-266 [PMID: 23546521 DOI: 10.1038/nrclinonc.2013.42]

52   **McGranahan N**, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. *Cancer Cell* 2015; **27**: 15-26 [PMID: 25584892 DOI: 10.1016/j.ccell.2014.12.001]

53   **S Franco S**, Szczesna K, Iliou MS, Al-Qahtani M, Mobasheri A, Kobolák J, Dinnyés A. In vitro models of cancer stem cells and clinical applications. *BMC Cancer* 2016; **16**: 738 [PMID: 27766946 DOI: 10.1186/s12885-016-2774-3]

54   **Ahuja N**, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. *J Clin Invest* 2014; **124**: 56-63 [PMID: 24382390 DOI: 10.1172/JCI69736]

55   **Brown R**, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. *Nat Rev Cancer* 2014; **14**: 747-753 [PMID: 25253389 DOI: 10.1038/nrc3819]

56   **Sharma A**, Vatapalli R, Abdelfatah E, Wyatt McMahon K, Kerner Z, A Guzzetta A, Singh J, Zahnow C, B Baylin S, Yerram S, Hu Y, Azad N, Ahuja N. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. *PLoS One* 2017; **12**: e0176139 [PMID: 28445481 DOI: 10.1371/journal.pone.0176139]

57   **Mao M**, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. *Clin Cancer Res* 2013; **19**: 657-667 [PMID: 23251002 DOI: 10.1158/1078-0432.CCR-11-1446]

58   **Huang TH**, Wu SY, Huang YJ, Wei PL, Wu AT, Chao TY. The identification and validation of Trichostatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells. *Am J*

Cancer Res 2017; **7**: 1227-1237 [PMID: 28560069]

59   **Pelosof L**, Yerram S, Armstrong T, Chu N, Danilova L, Yanagisawa B, Hidalgo M, Azad N, Herman JG. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. *Epigenetics* 2017; **12**: 540-550 [PMID: 27918237 DOI: 10.1080/15592294.2016.1265711]

60   **Vasaikar SV**, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res* 2018; **46**: D956-D963 [PMID: 29136027 DOI: 10.1093/nar/gkx1090]

61   **Pérez-Salvia M**, Esteller M. Bromodomain inhibitors and cancer therapy: From structures to applications. *Epigenetics* 2017; **12**: 323-339 [PMID: 27911230 DOI: 10.1080/15592294.2016.1265710]

62   **Aguirre-Gamboa R**, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG, Treviño V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. *PLoS One* 2013; **8**: e74250 [PMID: 24066126 DOI: 10.1371/journal.pone.0074250]

63   **Azad NS**, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. *Oncotarget* 2017; **8**: 35326-35338 [PMID: 28186961 DOI: 10.18632/oncotarget.15108]

64   **Bauman J**, Verschraegen C, Belinsky S, Muller C, Rutledge T, Fekrazad M, Ravindranathan M, Lee SJ, Jones D. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. *Cancer Chemother Pharmacol* 2012; **69**: 547-554 [PMID: 21901396 DOI: 10.1007/s00280-011-1729-2]

65   **Overman MJ**, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. *Oncotarget* 2016; **7**: 67495-67506 [PMID: 27542211 DOI: 10.18632/oncotarget.11317]

66   **Schwartsmann G**, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. *Invest New Drugs* 2000; **18**: 83-91 [PMID: 10830142]

67   **Appleton K**, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. *J Clin Oncol* 2007; **25**: 4603-4609 [PMID: 17925555 DOI: 10.1200/JCO.2007.10.8688]

68   **Garrido-Laguna I**, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. *Invest New Drugs* 2013; **31**: 1257-1264 [PMID: 23504398 DOI: 10.1007/s10637-013-9947-6]

69   **Toden S**, Tran HM, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. *Oncotarget* 2016; **7**: 16158-16171 [PMID: 26930714 DOI: 10.18632/oncotarget.7567]

70   **Yang PM**, Lin YT, Shun CT, Lin SH, Wei TT, Chuang SH, Wu MS, Chen CC. Zebularine inhibits tumorigenesis and stemness of colorectal cancer *via* p53-dependent endoplasmic reticulum stress. *Sci Rep* 2013; **3**: 3219 [PMID: 24225777 DOI: 10.1038/srep03219]

71   **Feldman M**, Levy D. Peptide inhibition of the SETD6 methyltransferase catalytic activity. *Oncotarget* 2017; **9**: 4875-4885 [PMID: 29435148 DOI: 10.18632/oncotarget.23591]

72   **Kaniskan HÜ**, Eram MS, Zhao K, Szewczyk MM, Yang X, Schmidt K, Luo X, Xiao S, Dai M, He F, Zang I, Lin Y, Li F, Dobrovetsky E, Smil D, Min SJ, Lin-Jones J, Schapira M, Atadja P, Li E, Barsyte-Lovejoy D, Arrowsmith CH, Brown PJ, Liu F, Yu Z, Vedadi M, Jin J. Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3). *J Med Chem* 2018; **61**: 1204-1217 [PMID: 29244490 DOI: 10.1021/acs.jmedchem.7b01674]

73   **Wu H**, Zheng W, Eram MS, Vhuiyan M, Dong A, Zeng H, He H, Brown P, Frankel A, Vedadi M, Luo M, Min J. Structural basis of arginine asymmetrical dimethylation by PRMT6. *Biochem J* 2016; **473**: 3049-3063 [PMID: 27480107 DOI: 10.1042/BCJ20160537]

74   **Chimenti F**, Bizzarri B, Maccioni E, Secci D, Bolasco A, Chimenti P, Fioravanti R, Granese A, Carradori S, Tosi F, Ballario P, Vernarecci S, Filetici P. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl)hydrazone]. *J Med Chem* 2009; **52**: 530-536 [PMID: 19099397 DOI: 10.1021/jm800885d]

75   **Aquea F**, Timmermann T, Herrera-Vásquez A. Chemical inhibition of the histone acetyltransferase activity in Arabidopsis thaliana. *Biochem Biophys Res Commun* 2017; **483**: 664-668 [PMID: 27993678 DOI: 10.1016/j.bbrc.2016.12.086]

76   **Wheler JJ**, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. *Cancer Chemother Pharmacol* 2014; **73**: 495-501 [PMID: 24435060 DOI: 10.1007/s00280-014-2384-1]

77   **Münster P**, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. *J Clin Oncol* 2007; **25**: 1979-1985 [PMID: 17513804]

78   **Pili R**, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. *Br J Cancer* 2012; **106**: 77-84 [PMID: 22134508 DOI: 10.1038/bjc.2011.527]

79   **Ngamphaiboon N**, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. *Invest New Drugs* 2015; **33**: 225-232 [PMID: 25371323 DOI: 10.1007/s10637-014-0174-6]

80   **Strickler JH**, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. *Cancer Chemother Pharmacol* 2012; **70**: 251-258 [PMID: 22744359 DOI: 10.1007/s00280-012-1911-1]

81   **Ree AH**, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K.

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. *Lancet Oncol* 2010; **11**: 459-464 [PMID: 20378407 DOI: 10.1016/S1470-2045(10)70058-9]

82   **Wilson PM**, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. *Cancer Chemother Pharmacol* 2010; **65**: 979-988 [PMID: 20062993 DOI: 10.1007/s00280-009-1236-x]

83   **Fakih MG**, Groman A, McMahon J, Wilding G, Muindi JR. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. *Cancer Chemother Pharmacol* 2012; **69**: 743-751 [PMID: 22020318 DOI: 10.1007/s00280-011-1762-1]

84   **Munster PN**, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. *Br J Cancer* 2009; **101**: 1044-1050 [PMID: 19738609 DOI: 10.1038/sj.bjc.6605293]

85   **Deming DA**, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. *Invest New Drugs* 2014; **32**: 323-329 [PMID: 24114123 DOI: 10.1007/s10637-013-0035-8]

86   **Whitehead RP**, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). *Invest New Drugs* 2009; **27**: 469-475 [PMID: 18941712 DOI: 10.1007/s10637-008-9190-8]

87   **Pauer LR**, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S, Nemunaitis J. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. *Cancer Invest* 2004; **22**: 886-896 [PMID: 15641487]

88   **Patel KR**, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. *Ann N Y Acad Sci* 2011; **1215**: 161-169 [PMID: 21261655 DOI: 10.1111/j.1749-6632.2010.05853.x]

89   **Rotili D**, Tarantino D, Nebbioso A, Paolini C, Huidobro C, Lara E, Mellini P, Lenoci A, Pezzi R, Botta G, Lahtela-Kakkonen M, Poso A, Steinkühler C, Gallinari P, De Maria R, Fraga M, Esteller M, Altucci L, Mai A. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. *J Med Chem* 2012; **55**: 10937-10947 [PMID: 23189967 DOI: 10.1021/jm3011614]

90   **Lin H**, Li Q, Li Q, Zhu J, Gu K, Jiang X, Hu Q, Feng F, Qu W, Chen Y, Sun H. Small molecule KDM4s inhibitors as anti-cancer agents. *J Enzyme Inhib Med Chem* 2018; **33**: 777-793 [PMID: 29651880 DOI: 10.1080/14756366.2018.1455676]

91   **Bar-Sela G**, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. *Curr Med Chem* 2010; **17**: 190-197 [PMID: 20214562 DOI: 10.2174/092986710790149738]

92   **Wang J**, Chen C, Wang S, Zhang Y, Yin P, Gao Z, Xu J, Feng D, Zuo Q, Zhao R, Chen T. Bufalin Inhibits HCT116 Colon Cancer Cells and Its Orthotopic Xenograft Tumor in Mice Model through Genes Related to Apoptotic and PTEN/AKT Pathways. *Gastroenterol Res Pract* 2015; **2015**: 457193 [PMID: 26770191 DOI: 10.1155/2015/457193]

93   **Wapenaar H**, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. *Clin Epigenetics* 2016; **8**: 59 [PMID: 27231488 DOI: 10.1186/s13148-016-0225-2]

94   **Fogelman D**, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. *Cancer Med* 2018; **7**: 5382-5393 [PMID: 30123970 DOI: 10.1002/cam4.1703]

95   **Chu-Farseeva YY**, Mustafa N, Poulsen A, Tan EC, Yen JJY, Chng WJ, Dymock BW. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. *Eur J Med Chem* 2018; **158**: 593-619 [PMID: 30243158 DOI: 10.1016/j.ejmech.2018.09.024]

96   **Kobza KA**, Chaiseeda K, Sarath G, Takacs JM, Zempleni J. Biotinyl-methyl 4-(amidomethyl)benzoate is a competitive inhibitor of human biotinidase. *J Nutr Biochem* 2008; **19**: 826-832 [PMID: 18479898 DOI: 10.1016/j.jnutbio.2007.11.002]

97   **Moustakim M**, Clark PG, Trulli L, Fuentes de Arriba AL, Ehebauer MT, Chaikuad A, Murphy EJ, Mendez-Johnson J, Daniels D, Hou CD, Lin YH, Walker JR, Hui R, Yang H, Dorrell L, Rogers CM, Monteiro OP, Fedorov O, Huber KV, Knapp S, Heer J, Dixon DJ, Brennan PE. Discovery of a PCAF Bromodomain Chemical Probe. *Angew Chem Int Ed Engl* 2017; **56**: 827-831 [PMID: 27966810 DOI: 10.1002/anie.201610816]

98   **He Y**, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, Shaw B, The J, Lima-Fernandes E, Szewczyk MM, Cheng D, Klinge KL, Li HQ, Pliushchev M, Algire MA, Maag D, Guo J, Dietrich J, Panchal SC, Petros AM, Sweis RF, Torrent M, Bigelow LJ, Senisterra G, Li F, Kennedy S, Wu Q, Osterling DJ, Lindley DJ, Gao W, Galasinski S, Barsyte-Lovejoy D, Vedadi M, Buchanan FG, Arrowsmith CH, Chiang GG, Sun C, Pappano WN. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. *Nat Chem Biol* 2017; **13**: 389-395 [PMID: 28135237 DOI: 10.1038/nchem-bio.2306]